Policy | July 27, 2022
Pharmaceuticals industry under Atmanirbhar Bharat programme
India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.
India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.
The Union Minister reviewed DST-supported SATHI-BHU facility
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
India’s traditional medicine systems have also earned formal recognition in key bilateral trade agreements
Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Subscribe To Our Newsletter & Stay Updated
